NextCell Pharma AB (SE:NXTCL)
:NXTCL
Top Page
NextCell Pharma AB
(NXTCL)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr1.50
▲(63.04% Upside)
Action:ReiteratedDate:03/07/26
Overall score is weighed down primarily by weak financial performance (persistent losses, negative margins, and significant cash burn), partially offset by a debt-free balance sheet. Technical signals are mixed with modest longer-term support but weak near-term trend. Valuation remains challenging due to negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
Recurring revenue from stem cell banking
The Cellaviva stem cell banking business provides contract-based, fee-for-service revenue that is relatively steady versus R&D cycles. This recurring service income creates a predictable cash inflow stream that partially offsets development volatility and supports ongoing operations and patient-facing capabilities over the medium term.
Negative Factors
Persistent negative cash flow
Sustained large negative operating and free cash flow steadily depletes reserves and forces reliance on external funding. Over the medium term this increases dilution risk, constrains discretionary investment, and may compress runway for clinical programs and commercial growth unless operating performance or financing changes materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue from stem cell banking
The Cellaviva stem cell banking business provides contract-based, fee-for-service revenue that is relatively steady versus R&D cycles. This recurring service income creates a predictable cash inflow stream that partially offsets development volatility and supports ongoing operations and patient-facing capabilities over the medium term.
Read all positive factors
NextCell Pharma AB (NXTCL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr147.71M
Dividend YieldN/A
Average Volume (3M)237.08K
Price to Earnings (P/E)―
Beta (1Y)<0.01
Revenue Growth2.56%
EPS Growth52.76%
CountrySE
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding111,392,960
10 Day Avg. Volume155,192
30 Day Avg. Volume237,081
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.36
Price to Sales (P/S)8.24
P/FCF Ratio-2.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.4
Revenue Forecast (FY)kr13.90M
NextCell Pharma AB Business Overview & Revenue Model
Company Description
NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product,...
How the Company Makes Money
NextCell Pharma AB generates revenue primarily through the development and commercialization of its proprietary stem cell-based treatments. The company earns money by advancing its products through clinical trials and eventually licensing them to ...
NextCell Pharma AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.88M | 10.94M | 10.66M | 10.11M | 5.59M | 3.91M |
| Gross Profit | -22.01M | -35.87M | -4.56M | -884.83K | -22.26M | -14.53M |
| EBITDA | -38.59M | -32.63M | -40.99M | -39.36M | -34.10M | -24.21M |
| Net Income | -40.89M | -35.14M | -41.96M | -39.81M | -34.08M | -24.56M |
Balance Sheet | ||||||
| Total Assets | 63.92M | 76.73M | 81.29M | 88.83M | 124.66M | 155.63M |
| Cash, Cash Equivalents and Short-Term Investments | 26.03M | 38.72M | 46.79M | 50.03M | 97.12M | 139.17M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 13.32M | 10.34M | 13.69M | 13.10M | 9.12M | 5.53M |
| Stockholders Equity | 50.60M | 66.39M | 67.60M | 75.73M | 115.54M | 150.09M |
Cash Flow | ||||||
| Free Cash Flow | -55.54M | -43.05M | -37.86M | -47.92M | -40.90M | -26.30M |
| Operating Cash Flow | -48.85M | -38.86M | -37.78M | -43.83M | -33.31M | -25.58M |
| Investing Cash Flow | -6.99M | -4.24M | -83.51K | -4.10M | -9.37M | -5.84M |
| Financing Cash Flow | 69.76M | 35.03M | 34.63M | 835.66K | 608.17K | 148.63M |
NextCell Pharma AB Technical Analysis
Positive
0.92
Price Trends
1.36
Negative
1.10
Positive
1.07
Positive
Market Momentum
-0.01
Negative
54.86
Neutral
73.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NXTCL, the sentiment is Positive. The current price of 0.92 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.36, and below the 200-day MA of 1.07, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.86 is Neutral, neither overbought nor oversold. The STOCH value of 73.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:NXTCL.
NextCell Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr105.70M | -1.81 | -72.82% | ― | 40.91% | 57.92% | |
44 Neutral | kr147.71M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr94.99M | -3.17 | -21.31% | ― | -67.00% | 13.62% | |
43 Neutral | kr38.92M | -1.03 | -457.91% | ― | ― | -19.35% | |
42 Neutral | kr24.42M | -1.86 | -120.13% | ― | ― | 49.09% | |
42 Neutral | kr122.63M | -1.34 | -294.38% | ― | 186.74% | 73.17% |
* Healthcare Sector Average
SE:NXTCL
NextCell Pharma AB
1.38
0.31
28.79%
SE:ALZ
Alzinova AB
0.59
-1.28
-68.36%
SE:BIOSGN
Biosergen AB
10.00
-19.60
-66.22%
SE:NICA
Nanologica AB
0.36
-0.46
-56.19%
SE:BIOVIC.B
Biovica International AB Class B
0.38
-0.26
-40.47%
SE:MODTX
Modus Therapeutics Holding AB
0.34
-0.15
-30.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.